Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Crohn Disease: HELP
Articles from USA
Based on 3,164 articles published since 2007

These are the 3164 published articles about Crohn Disease that originated from USA during 2007-2018.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Surgical Management of Crohn Disease in Children: Guidelines From the Paediatric IBD Porto Group of ESPGHAN. 2017

Amil-Dias, Jorge / Kolacek, Sanja / Turner, Dan / Pærregaard, Anders / Rintala, Risto / Afzal, Nadeem A / Karolewska-Bochenek, Katarzyna / Bronsky, Jiri / Chong, Sonny / Fell, John / Hojsak, Iva / Hugot, Jean-Pierre / Koletzko, Sibylle / Kumar, Devinder / Lazowska-Przeorek, Izabella / Lillehei, Craig / Lionetti, Paolo / Martin-de-Carpi, Javier / Pakarinen, Mikko / Ruemmele, Frank M / Shaoul, Ron / Spray, Christine / Staiano, Annamaria / Sugarman, Ian / Wilson, David C / Winter, Harland / Kolho, Kaija-Leena / Anonymous551042. ·*Department of Pediatrics, Centro Hospitalar, S. João, Porto, Portugal †Children's Hospital Zagreb, Faculty of Medicine, Zagreb, Croatia ‡The Juliet Keidan Institute of Pediatric Gastroenterology & Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel §Department of Pediatrics, Hvidovre University Hospital, Hvidovre, Denmark ||Pediatric Surgery, Children's Hospital, University of Helsinki, Helsinki, Finland ¶Department of Pediatric Gastroenterology, University Hospital Southampton, Southampton, UK #Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland **Department of Pediatrics, University Hospital Motol, Prague, Czech Republic ††Queen Mary's Hospital for Children, Epsom and St Helier NHS Trust, Surrey ‡‡Chelsea and Westminster Hospital, London, UK §§Paris-Diderot Sorbonne-Paris-Cité University and Robert Debré Hospital, Paris, France ||||Pediatric Gastroenterology and Hepatology, Dr. von Hauner Children's Hospital, Ludwig Maximilians-University, Munich, Germany ¶¶St George's, University of London, London, UK ##Boston Children's Hospital and Harvard Medical School, Boston, MA ***Department NEUROFARBA, University of Florence - Meyer Hospital, Florence, Italy †††Unit for the Comprehensive Care of Pediatric Inflammatory Bowel Disease, Hospital Sant Joan de Déu, Barcelona, Spain ‡‡‡Department of Pediatric Gastroenterology, Necker Enfants Malades University Hospital, Sorbonne Paris Cité University, Paris Descartes University, Institut IMAGINE - INSERM U1163, Paris, France §§§Pediatric Gastroenterology Institute, Ruth Children's Hospital, Rambam Medical Center, Haifa, Israel ||||||Department of Pediatric Gastroenterology, Bristol Royal Hospital for Children, Bristol, UK ¶¶¶Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II," Naples, Italy ###Department of Pediatric Surgery, Leeds Children's Hospital, Leeds General Infirmary, Leeds, UK ****Child Life and Health, University of Edinburgh, Scotland, UK ††††MassGeneral Hospital for Children, Harvard Medical School, Boston, MA ‡‡‡‡Children's Hospital, University of Helsinki, Helsinki, Finland. ·J Pediatr Gastroenterol Nutr · Pubmed #28267075.

ABSTRACT: The incidence of Crohn disease (CD) has been increasing and surgery needs to be contemplated in a substantial number of cases. The relevant advent of biological treatment has changed but not eliminated the need for surgery in many patients. Despite previous publications on the indications for surgery in CD, there was a need for a comprehensive review of existing evidence on the role of elective surgery and options in pediatric patients affected with CD. We present an expert opinion and critical review of the literature to provide evidence-based guidance to manage these patients. Indications, surgical options, risk factors, and medications in pre- and perioperative period are reviewed in the light of available evidence. Risks and benefits of surgical options are addressed. An algorithm is proposed for the management of postsurgery monitoring, timing for follow-up endoscopy, and treatment options.

2 Guideline The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. 2016

Nguyen, Geoffrey C / Seow, Cynthia H / Maxwell, Cynthia / Huang, Vivian / Leung, Yvette / Jones, Jennifer / Leontiadis, Grigorios I / Tse, Frances / Mahadevan, Uma / van der Woude, C Janneke / Anonymous7610852 / Anonymous7620852. ·Mount Sinai Hospital Centre for Inflammatory Bowel Disease, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: geoff.nguyen@utoronto.ca. · Departments of Medicine & Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. · Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada. · Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. · Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada. · Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. · Department of Medicine, McMaster University, Hamilton, Ontario, Canada. · Department of Medicine, University of California, San Francisco, San Francisco, California. · Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. ·Gastroenterology · Pubmed #26688268.

ABSTRACT: BACKGROUND & AIMS: The management of inflammatory bowel disease (IBD) poses a particular challenge during pregnancy because the health of both the mother and the fetus must be considered. METHODS: A systematic literature search identified studies on the management of IBD during pregnancy. The quality of evidence and strength of recommendations were rated using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. RESULTS: Consensus was reached on 29 of the 30 recommendations considered. Preconception counseling and access to specialist care are paramount in optimizing disease management. In general, women on 5-ASA, thiopurine, or anti-tumor necrosis factor (TNF) monotherapy for maintenance should continue therapy throughout pregnancy. Discontinuation of anti-TNF therapy or switching from combination therapy to monotherapy may be considered in very select low-risk patients. Women who have a mild to moderate disease flare while on optimized 5-ASA or thiopurine therapy should be managed with systemic corticosteroid or anti-TNF therapy, and those with a corticosteroid-resistant flare should start anti-TNF therapy. Endoscopy or urgent surgery should not be delayed during pregnancy if indicated. Decisions regarding cesarean delivery should be based on obstetric considerations and not the diagnosis of IBD alone, with the exception of women with active perianal Crohn's disease. With the exception of methotrexate, the use of medications for IBD should not influence the decision to breast-feed and vice versa. Live vaccinations are not recommended within the first 6 months of life in the offspring of women who were on anti-TNF therapy during pregnancy. CONCLUSIONS: Optimal management of IBD before and during pregnancy is essential to achieving favorable maternal and neonatal outcomes.

3 Guideline Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. 2015

Pennazio, Marco / Spada, Cristiano / Eliakim, Rami / Keuchel, Martin / May, Andrea / Mulder, Chris J / Rondonotti, Emanuele / Adler, Samuel N / Albert, Joerg / Baltes, Peter / Barbaro, Federico / Cellier, Christophe / Charton, Jean Pierre / Delvaux, Michel / Despott, Edward J / Domagk, Dirk / Klein, Amir / McAlindon, Mark / Rosa, Bruno / Rowse, Georgina / Sanders, David S / Saurin, Jean Christophe / Sidhu, Reena / Dumonceau, Jean-Marc / Hassan, Cesare / Gralnek, Ian M. ·Division of Gastroenterology, San Giovanni Battista University Teaching Hospital, Turin, Italy. · Digestive Endoscopy Unit, Catholic University, Rome, Italy. · Department of Gastroenterology, Chaim Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University Tel-Hashomer, Israel. · Klinik für Innere Medizin, Bethesda Krankenhaus Bergedorf, Hamburg, Germany. · Department of Medicine II, Sana Klinikum, Offenbach, Germany. · Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands. · Gastroenterology Unit, Ospedale Valduce, Como, Italy. · Division of Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel. · Department of Medicine I, Johann Wolfgang Goethe University Frankfurt, Frankfurt, Germany. · Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Service d'Hépato-gastro-entérologie, Paris, France. · Medizinische Klinik, Evangelisches Krankenhaus, Düsseldorf, Germany. · Department of Hepato-Gastroenterology, Nouvel Hôpital Civil, University Hospital of Strasbourg, Strasbourg, France. · Royal Free Unit for Endoscopy and Centre for Gastroenterology, The Royal Free Hospital and University College London, London, UK. · Department of Medicine B, University of Münster, Münster, Germany. · Institute of Gastroenterology and Liver Diseases, Ha'emek Medical Center Afula, Israel, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology Haifa, Israel. · Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. · Gastroenterology Department, Centro Hospitalar do Alto Ave, Guimarães, Portugal. · Clinical Psychology Unit, Department of Psychology, University of Sheffield. · Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France. · Gedyt Endoscopy Center, Buenos Aires, Argentina. ·Endoscopy · Pubmed #25826168.

ABSTRACT: This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). The Guideline was also reviewed and endorsed by the British Society of Gastroenterology (BSG). It addresses the roles of small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders. Main recommendations 1 ESGE recommends small-bowel video capsule endoscopy as the first-line investigation in patients with obscure gastrointestinal bleeding (strong recommendation, moderate quality evidence). 2 In patients with overt obscure gastrointestinal bleeding, ESGE recommends performing small-bowel capsule endoscopy as soon as possible after the bleeding episode, optimally within 14 days, in order to maximize the diagnostic yield (strong recommendation, moderate quality evidence). 3 ESGE does not recommend the routine performance of second-look endoscopy prior to small-bowel capsule endoscopy; however whether to perform second-look endoscopy before capsule endoscopy in patients with obscure gastrointestinal bleeding or iron-deficiency anaemia should be decided on a case-by-case basis (strong recommendation, low quality evidence). 4 In patients with positive findings at small-bowel capsule endoscopy, ESGE recommends device-assisted enteroscopy to confirm and possibly treat lesions identified by capsule endoscopy (strong recommendation, high quality evidence). 5 ESGE recommends ileocolonoscopy as the first endoscopic examination for investigating patients with suspected Crohn's disease (strong recommendation, high quality evidence). In patients with suspected Crohn's disease and negative ileocolonoscopy findings, ESGE recommends small-bowel capsule endoscopy as the initial diagnostic modality for investigating the small bowel, in the absence of obstructive symptoms or known stenosis (strong recommendation, moderate quality evidence).ESGE does not recommend routine small-bowel imaging or the use of the PillCam patency capsule prior to capsule endoscopy in these patients (strong recommendation, low quality evidence). In the presence of obstructive symptoms or known stenosis, ESGE recommends that dedicated small bowel cross-sectional imaging modalities such as magnetic resonance enterography/enteroclysis or computed tomography enterography/enteroclysis should be used first (strong recommendation, low quality evidence). 6 In patients with established Crohn's disease, based on ileocolonoscopy findings, ESGE recommends dedicated cross-sectional imaging for small-bowel evaluation since this has the potential to assess extent and location of any Crohn's disease lesions, to identify strictures, and to assess for extraluminal disease (strong recommendation, low quality evidence). In patients with unremarkable or nondiagnostic findings from such cross-sectional imaging of the small bowel, ESGE recommends small-bowel capsule endoscopy as a subsequent investigation, if deemed to influence patient management (strong recommendation, low quality evidence). When capsule endoscopy is indicated, ESGE recommends use of the PillCam patency capsule to confirm functional patency of the small bowel (strong recommendation, low quality evidence). 7 ESGE strongly recommends against the use of small-bowel capsule endoscopy for suspected coeliac disease but suggests that capsule endoscopy could be used in patients unwilling or unable to undergo conventional endoscopy (strong recommendation, low quality evidence).

4 Guideline Guidelines for imaging of Crohn's perianal fistulizing disease. 2015

Ong, Eugene M W / Ghazi, Leyla J / Schwartz, David A / Mortelé, Koenraad J / Anonymous1540823. ·*Department of Radiology, Division of Clinical MRI, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; †Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland; and ‡Department of Gastroenterology and Hepatology, Vanderbilt University, Nashville, Tennessee. ·Inflamm Bowel Dis · Pubmed #25751067.

ABSTRACT: -- No abstract --

5 Guideline Guidelines for the multidisciplinary management of Crohn's perianal fistulas: summary statement. 2015

Schwartz, David A / Ghazi, Leyla J / Regueiro, Miguel / Fichera, Alessandro / Zoccali, Marco / Ong, Eugene M W / Mortelé, Koenraad J / Anonymous1530823. ·*Department of Gastroenterology and Hepatology, Vanderbilt University, Nashville, Tennessee; †Department of Gastroenterology and Hepatology, University of Maryland Medical Center, Baltimore, Maryland; ‡University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; §Division of General Surgery, Department of Surgery, University of Washington Medical Center, Seattle, Washington; ‖Department of Surgery, Weill Medical College of Cornell University, New York, New York; and ¶Division of Clinical MRI, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. ·Inflamm Bowel Dis · Pubmed #25751066.

ABSTRACT: -- No abstract --

6 Guideline Guidelines for the surgical treatment of Crohn's perianal fistulas. 2015

Fichera, Alessandro / Zoccali, Marco / Anonymous5490822. ·*Section Gastrointestinal Surgery, Division of General Surgery. Department of Surgery, University of Washington Medical Center, Seattle, Washington; and †Department of Surgery, New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York. ·Inflamm Bowel Dis · Pubmed #25738380.

ABSTRACT: -- No abstract --

7 Guideline A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. 2014

Gecse, Krisztina B / Bemelman, Willem / Kamm, Michael A / Stoker, Jaap / Khanna, Reena / Ng, Siew C / Panés, Julián / van Assche, Gert / Liu, Zhanju / Hart, Ailsa / Levesque, Barrett G / D'Haens, Geert / Anonymous1380798 / Anonymous1390798. ·Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Robarts Research Institute, Amsterdam, The Netherlands. · Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. · St. Vincent's Hospital and University of Melbourne, Melbourne, Australia. · Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. · Robarts Research Institute, London, Ontario, Canada University of Western Ontario, London, Ontario, Canada. · Department of Medicine and Therapeutics, Institute of Digestive Disease, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, Hong Kong. · Department of Gastroenterology, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain. · Department of Gastroenterology, University of Leuven, Leuven, Belgium. · Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China. · APRG, Imperial College, London, UK IBD Unit, St. Mark's Hospital, London, UK. · Robarts Research Institute, San Diego, CA, USA Division of Gastroenterology, University of California San Diego, La Jolla, California, USA. ·Gut · Pubmed #24951257.

ABSTRACT: OBJECTIVE: To develop a consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease (pCD), based on best available evidence. METHODS: Based on a systematic literature review, statements were formed, discussed and approved in multiple rounds by the 20 working group participants. Consensus was defined as at least 80% agreement among voters. Evidence was assessed using the modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria. RESULTS: Highest diagnostic accuracy can only be established if a combination of modalities is used. Drainage of sepsis is always first line therapy before initiating immunosuppressive treatment. Mucosal healing is the goal in the presence of proctitis. Whereas antibiotics and thiopurines have a role as adjunctive treatments in pCD, anti-tumour necrosis factor (anti-TNF) is the current gold standard. The efficacy of infliximab is best documented although adalimumab and certolizumab pegol are moderately effective. Oral tacrolimus could be used in patients failing anti-TNF therapy. Definite surgical repair is only of consideration in the absence of luminal inflammation. CONCLUSIONS: Based on a multidisciplinary approach, items relevant for fistula management were identified and algorithms on diagnosis and treatment of pCD were developed.

8 Guideline Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. 2014

Ruemmele, F M / Veres, G / Kolho, K L / Griffiths, A / Levine, A / Escher, J C / Amil Dias, J / Barabino, A / Braegger, C P / Bronsky, J / Buderus, S / Martín-de-Carpi, J / De Ridder, L / Fagerberg, U L / Hugot, J P / Kierkus, J / Kolacek, S / Koletzko, S / Lionetti, P / Miele, E / Navas López, V M / Paerregaard, A / Russell, R K / Serban, D E / Shaoul, R / Van Rheenen, P / Veereman, G / Weiss, B / Wilson, D / Dignass, A / Eliakim, A / Winter, H / Turner, D / Anonymous4940796 / Anonymous4950796. ·Department of Paediatric Gastroenterology, APHP Hôpital Necker Enfants Malades, 149 Rue de Sèvres 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, 2 Rue de l'École de Médecine, 75006 Paris, France; INSERM U989, Institut IMAGINE, 24 Bd Montparnasse, 75015 Paris, France. Electronic address: frank.ruemmele@nck.aphp.fr. · Department of Paediatrics I, Semmelweis University, Bókay János str. 53, 1083 Budapest, Hungary. · Department of Gastroenterology, Helsinki University Hospital for Children and Adolescents, Stenbäckinkatu 11, P.O. Box 281, 00290 Helsinki, Finland. · Department of Paediatrics, Hospital for Sick Children, University of Toronto, 555 University Avenue, M5G 1X8 Toronto, ON, Canada. · Paediatric Gastroenterology and Nutrition Unit, Tel Aviv University, Edith Wolfson Medical Center, 62 HaLohamim Street, 58100 Holon, Israel. · Department of Paediatric Gastroenterology, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, Netherlands. · Unit of Paediatric Gastroenterology, Hospital S. João, A Hernani Monteiro, 4202-451, Porto, Portugal. · Gastroenterology and Endoscopy Unit, Istituto G. Gaslini, Via G. Gaslini 5, 16148 Genoa, Italy. · Division of Gastroenterology and Nutrition, and Children's Research Center, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland. · Department of Pediatrics, University Hospital Motol, Uvalu 84, 150 06 Prague, Czech Republic. · Department of Paediatrics, St. Marien Hospital, Robert-Koch-Str.1, 53115 Bonn, Germany. · Department of Paediatric Gastroenterolgoy, Hepatology and Nutrition, Hospital Sant Joan de Déu, Paseo Sant Joan de Déu 2, 08950 Barcelona, Spain. · Department of Pediatrics, Centre for Clinical Research, Entrance 29, Västmanland Hospital, 72189 Västerås/Karolinska Institutet, Stockholm, Sweden. · Department of Gastroenterology and Nutrition, Hopital Robert Debré, 48 Bd Sérurier, APHP, 75019 Paris, France; Université Paris-Diderot Sorbonne Paris-Cité, 75018 Paris France. · Department of Gastroenterology, Hepatology and Feeding Disorders, Instytut Pomnik Centrum Zdrowia Dziecka, Ul. Dzieci Polskich 20, 04-730 Warsaw, Poland. · Department of Paediatric Gastroenterology, Children's Hospital, University of Zagreb Medical School, Klaićeva 16, 10000 Zagreb, Croatia. · Department of Paediatric Gastroenterology, Dr. von Hauner Children's Hospital, Lindwurmstr. 4, 80337 Munich, Germany. · Department of Gastroenterology and Nutrition, Meyer Children's Hospital, Viale Gaetano Pieraccini 24, 50139 Florence, Italy. · Department of Translational Medical Science, Section of Paediatrics, University of Naples "Federico II", Via S. Pansini, 5, 80131 Naples, Italy. · Paediatric Gastroenterology and Nutrition Unit, Hospital Materno Infantil, Avda. Arroyo de los Ángeles s/n, 29009 Málaga, Spain. · Department of Paediatrics 460, Hvidovre University Hospital, Kettegård Allé 30, 2650 Hvidovre, Denmark. · Department of Paediatric Gastroenterology, Yorkhill Hospital, Dalnair Street, Glasgow G3 8SJ, United Kingdom. · 2nd Department of Paediatrics, "Iuliu Hatieganu" University of Medicine and Pharmacy, Emergency Children's Hospital, Crisan nr. 5, 400177 Cluj-Napoca, Romania. · Department of Pediatric Gastroenterology and Nutrition, Rambam Health Care Campus Rappaport Faculty Of Medicine, 6 Ha'alya Street, P.O. Box 9602, 31096 Haifa, Israel. · Department of Paediatric Gastroenterology, Hepatology and Nutrition, University Medical Center Groningen, P.O. Box 30001, 9700 RB Groningen, Netherlands. · Department of Paediatric Gastroenterology and Nutrition, Children's University Hospital, Laarbeeklaan 101, 1090 Brussels, Belgium. · Paediatric Gastroenterology and Nutrition Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52625 Tel Hashomer, Israel. · Child Life and Health, Paediatric Gastroenterology, Royal Hospital for Sick Children, 9 Sciennes Road, Edinburgh EH9 1LF, United Kingdom. · Department of Medicine I, Agaplesion Markus Hospital, Wilhelm-Epstein-Str. 4, 60431 Frankfurt/Main, Gemany. · 33-Gastroenterology, Sheba Medical Center, 52621 Tel Hashomer, Israel. · Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Mass General Hospital for Children, 175 Cambridge Street, 02114 Boston, United States. · Pediatric Gastroenterology Unit, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel. ·J Crohns Colitis · Pubmed #24909831.

ABSTRACT: Children and adolescents with Crohn's disease (CD) present often with a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and emotional development of patients underlines the need for a specific management strategy of pediatric-onset CD. To develop the first evidenced based and consensus driven guidelines for pediatric-onset CD an expert panel of 33 IBD specialists was formed after an open call within the European Crohn's and Colitis Organisation and the European Society of Pediatric Gastroenterolog, Hepatology and Nutrition. The aim was to base on a thorough review of existing evidence a state of the art guidance on the medical treatment and long term management of children and adolescents with CD, with individualized treatment algorithms based on a benefit-risk analysis according to different clinical scenarios. In children and adolescents who did not have finished their growth, exclusive enteral nutrition (EEN) is the induction therapy of first choice due to its excellent safety profile, preferable over corticosteroids, which are equipotential to induce remission. The majority of patients with pediatric-onset CD require immunomodulator based maintenance therapy. The experts discuss several factors potentially predictive for poor disease outcome (such as severe perianal fistulizing disease, severe stricturing/penetrating disease, severe growth retardation, panenteric disease, persistent severe disease despite adequate induction therapy), which may incite to an anti-TNF-based top down approach. These guidelines are intended to give practical (whenever possible evidence-based) answers to (pediatric) gastroenterologists who take care of children and adolescents with CD; they are not meant to be a rule or legal standard, since many different clinical scenario exist requiring treatment strategies not covered by or different from these guidelines.

9 Guideline American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. 2013

Terdiman, Jonathan P / Gruss, Claudia B / Heidelbaugh, Joel J / Sultan, Shahnaz / Falck-Ytter, Yngve T / Anonymous4190776. ·Division of Gastroenterology, University of California, San Francisco School of Medicine, San Francisco, California. ·Gastroenterology · Pubmed #24267474.

ABSTRACT: -- No abstract --

10 Guideline Management of Crohn's disease in adults. 2009

Lichtenstein, Gary R / Hanauer, Stephen B / Sandborn, William J / Anonymous3670620. ·Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. gary.lichtenstein@uphs.upenn.edu ·Am J Gastroenterol · Pubmed #19174807.

ABSTRACT: Guidelines for clinical practice are intended to suggest preferable approaches to particular medical problems as established by interpretation and collation of scientifically valid research, derived from extensive review of published literature. When data that will withstand objective scrutiny are not available, a recommendation may be made based on a consensus of experts. Guidelines are intended to apply to the clinical situation for all physicians without regard to specialty. Guidelines are intended to be flexible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are inflexible and rarely violated. Given the wide range of choices in any health-care problem, the physician should select the course best suited to the individual patient and the clinical situation presented. These guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee. Expert opinion is solicited from the outset for the document. The quality of evidence upon which a specific recommendation is based is as follows: Grade A: Homogeneous evidence from multiple well-designed randomized (therapeutic) or cohort (descriptive) controlled trials, each involving a number of participants to be of sufficient statistical power. Grade B: Evidence from at least one large well-designed clinical trial with or without randomization, from cohort or case-control analytic studies, or well-designed meta-analysis. Grade C: Evidence based on clinical experience, descriptive studies, or reports of expert committees. The Committee reviews guidelines in depth, with participation from experienced clinicians and others in related fields. The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time.

11 Guideline Refractory inflammatory bowel disease in children. 2008

Oliva-Hemker, M / Escher, J C / Moore, D / Dubinksy, M / Hildebrand, H / Koda, Y K L / Murch, S / Sandhu, B / Seo, J K / Tanzi, M N / Warner, B / Anonymous5690604. ·Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD 21287-2631, USA. moliva@jhmi.edu ·J Pediatr Gastroenterol Nutr · Pubmed #18664886.

ABSTRACT: -- No abstract --

12 Guideline Practice parameters for the surgical management of Crohn's disease. 2007

Strong, Scott A / Koltun, Walter A / Hyman, Neil H / Buie, W Donald / Anonymous690574. ·Fletcher Allen Health Care, 111 Colchester Avenue, Fletcher 301, Burlington, Vermont 05401, USA. ·Dis Colon Rectum · Pubmed #17690937.

ABSTRACT: -- No abstract --

13 Editorial Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease. 2018

Colizzo, F P / Friedman, L S. ·Massachusetts General Hospital, Boston, MA, USA. · Newton-Wellesley Hospital, Newton, MA, USA. ·Aliment Pharmacol Ther · Pubmed #29226421.

ABSTRACT: -- No abstract --

14 Editorial Zeroing in on endoscopic and histologic mucosal healing to reduce the risk of colorectal neoplasia in inflammatory bowel disease. 2017

Saxena, Akriti P / Limdi, Jimmy K / Farraye, Francis A. ·Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA. · Division of Gastroenterology, The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom; Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom. ·Gastrointest Endosc · Pubmed #29146080.

ABSTRACT: -- No abstract --

15 Editorial Editorial: Endoscopic Scoring Systems in Crohn's Disease for Evaluation of Responsiveness to Treatment: Are we Ready for the Prime Time of Endoscopic Assessment? 2017

Buchner, Anna M / Lichtenstein, Gary R. ·Division of Gastroenterology at University of Pennsylvania, Philadelphia, Pennsylvania, USA. ·Am J Gastroenterol · Pubmed #28978952.

ABSTRACT: There are currently two validated endoscopic indices for evaluation of Crohn's disease (CD), the Crohn's disease Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score for Crohn's disease (SES-CD). The study by Khanna et al. evaluated the responsiveness of the SES-CD and CDEIS using data from a trial of adalimumab. The study used appropriate statistical methods to quantify responsiveness of the indices as assessed by blinded central readers. The SES-CD demonstrated numerically greater responsiveness to a treatment of known efficacy, suggestive that the SES-CD is more efficient outcome measure than the CDEIS. Removal of stenosis as an index item and adjusting for observed segments did not improve responsiveness. In the future, the implementation of the SES-CD into daily clinical practice may become a practical tool used by gastroenterologists when caring for patients with Crohn's disease. Further studies analyzing the responsiveness of the indices in combination with clinical and patients' driven outcomes are expected prior to the indices' use in "prime time".

16 Editorial Fecal Incontinence Among Patients With Crohn's Disease: Does Awareness Change Anything? 2017

Stewart, David B. ·Hershey, Pennsylvania. ·Dis Colon Rectum · Pubmed #28682961.

ABSTRACT: -- No abstract --

17 Editorial Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease. 2017

Stidham, R W / Waljee, A K. ·Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA. · Center for Clinical Management Research, Ann Arbor Veterans Affairs Healthcare System, Ann Arbor, MI, USA. ·Aliment Pharmacol Ther · Pubmed #28503867.

ABSTRACT: -- No abstract --

18 Editorial Editorial: variability in adalimumab trough and peak serum concentrations. 2017

Vande Casteele, N / Gils, A. ·Department of Medicine, University of California San Diego, La Jolla, CA, USA. · Robarts Clinical Trials Inc., Robarts Research Institute, London, ON, Canada. · Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. ·Aliment Pharmacol Ther · Pubmed #28474834.

ABSTRACT: -- No abstract --

19 Editorial Editorial: importance of definition of inflammatory bowel disease and an increased incidence in children. 2017

Everhov, Å H / Olén, O / Ludvigsson, J F. ·Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden. · Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. · Department of paediatric gastroenterology and nutrition, Sachs' Children and Youth Hospital, Stockholm, Sweden. · Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. · Department of Paediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden. · Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK. · Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. ·Aliment Pharmacol Ther · Pubmed #28417497.

ABSTRACT: -- No abstract --

20 Editorial The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. 2017

Sofia, M Anthony / Rubin, David T. ·Inflammatory Bowel Disease Center, University of Chicago Medicine, 5841 South Maryland Avenue, MC 4076, Chicago, IL, 60637, USA. masofia@uchicago.edu. · Inflammatory Bowel Disease Center, University of Chicago Medicine, 5841 South Maryland Avenue, MC 4076, Chicago, IL, 60637, USA. ·Dig Dis Sci · Pubmed #28197743.

ABSTRACT: The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn's disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.

21 Editorial Circulating Endothelial Progenitor Cells in Crohn's Disease: An EPiC in the Making? 2017

Dietrich, Catharine / Singh, Shree Ram. ·Stem Cell Regulation and Animal Aging Section, Basic Research Laboratory, National Cancer Institute, NIH, Frederick, MD, 21702, USA. · Stem Cell Regulation and Animal Aging Section, Basic Research Laboratory, National Cancer Institute, NIH, Frederick, MD, 21702, USA. singhshr@mail.nih.gov. ·Dig Dis Sci · Pubmed #28078527.

ABSTRACT: -- No abstract --

22 Editorial Is it a prime time for small-bowel colon video capsule endoscopy to cover both sides of the ileocecal valve in Crohn's disease? 2017

Shen, Bo. ·The Interventional IBD Unit, Digestive Disease and Surgery Institute, The Cleveland Clinic Foundation, Cleveland, Ohio, USA. ·Gastrointest Endosc · Pubmed #27986111.

ABSTRACT: -- No abstract --

23 Editorial How should we treat mild and moderate-severe Crohn's disease in 2017? A brief overview of available therapies. 2017

Winter, Rachel W / Burakoff, Robert. ·a Division of Gastroenterology, Hepatology and Endoscopy , Brigham and Women's Hospital , Boston , MA , USA. ·Expert Rev Gastroenterol Hepatol · Pubmed #27900879.

ABSTRACT: -- No abstract --

24 Editorial A whole animal chemical screen approach to identify modifiers of intestinal neutrophilic inflammation. 2017

Oehlers, Stefan H / Flores, Maria Vega / Hall, Christopher J / Wang, Liuyang / Ko, Dennis C / Crosier, Kathryn E / Crosier, Philip S. ·Department of Molecular Medicine and Pathology, School of Medical Sciences, University of Auckland, New Zealand. · Tuberculosis Research Program, Centenary Institute, Camperdown, NSW, Australia. · Sydney Medical School, The University of Sydney, Newtown, NSW, Australia. · Department of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, NC, USA. · Department of Medicine, School of Medicine, Duke University, Durham, NC, USA. ·FEBS J · Pubmed #27885812.

ABSTRACT: By performing two high-content small molecule screens on dextran sodium sulfate- and trinitrobenzene sulfonic acid-induced zebrafish enterocolitis models of inflammatory bowel disease, we have identified novel anti-inflammatory drugs from the John Hopkins Clinical Compound Library that suppress neutrophilic inflammation. Live imaging of neutrophil distribution was used to assess the level of acute inflammation and concurrently screen for off-target drug effects. Supporting the validity of our screening strategy, most of the anti-inflammatory drug hits were known antibiotics or anti-inflammatory agents. Novel hits included cholecystokinin (CCK) and dopamine receptor agonists. Using a pharmacological approach, we show that while CCK and dopamine receptor agonists alleviate enterocolitis-associated inflammation, receptor antagonists exacerbate inflammation in zebrafish. This work highlights the utility of small molecule screening in zebrafish enterocolitis models as a tool to identify novel bioactive molecules capable of modulating acute inflammation.

25 Editorial Sphincter-Sparing Surgery for Diffuse Crohn's Disease of the Large Intestine: Who Really Has a Choice? 2016

Strong, Scott A. ·Chicago, Illinois. ·Dis Colon Rectum · Pubmed #27824696.

ABSTRACT: -- No abstract --